Pilot Feasibility and Safety Study of Hydrogen Gas Inhalation in Locally Advanced Head and Neck Cancer Patients.
Imjai Chitapanarux, Wimrak Onchan, Somvilai Chakrabandhu, Pooriwat Muangwong, Narongchai Autsavapromporn, Tapanut Ariyanon, Junji Akagi, Akira Mizoo · OncoTargets and therapy · 2024
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 80 patients with locally advanced head and neck cancer (LAHNC), all patients received 33 fractions of H₂ gas inhalation on the same day as the IMRT. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how inhaled hydrogen gas affected the outcomes measured in 80 patients with locally advanced head and neck cancer (LAHNC). All patients received 33 fractions of H₂ gas inhalation on the same day as the IMRT.
What the Researchers Studied
The researchers studied 80 patients with locally advanced head and neck cancer (LAHNC). The study used a human clinical study.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 99.99% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 99.99% source-reported H₂ gas concentration; 1.2 L/min H₂ flow (1200 mL/min H₂); administered 1–2 hours before irradiation. All patients received 33 fractions of H₂ gas inhalation on the same day as the IMRT. The authors concluded that H₂ gas inhalation combined with CCRT is feasible and safe for patients with LAHNC. Hydrogen (H₂) gas inhalation might alleviate acute radiotherapy toxicities by scavenging free radicals produced by ionizing radiation and anti-inflammatory properties.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a human clinical study. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 80 patients with locally advanced head and neck cancer (LAHNC). The reported sample size was 10. The study used a human clinical study. The hydrogen delivery method was inhaled hydrogen gas. The source-reported hydrogen concentration was 99.99% source-reported H₂ gas concentration.
Limitations and Safety
Reported limitations: Most of the available data comes from pilot or early-phase studies, which often involve small sample sizes and lack the robust evidence needed to establish definitive safety and efficacy profiles. The secondary endpoints were safety profiles during H₂ gas inhalation (vital signs and symptoms related to H₂ gas inhalation) and acute toxicities during CCRT. No adverse events related to H₂ gas inhalation, such as cough, nasal bleeding, dizziness, headache, nausea, or vomiting, were reported.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.